Loading
A medication taken with meals that binds dietary phosphate in the gut so it is not absorbed - the cornerstone of phosphate control in advanced CKD.
Phosphorus binders act in the GI tract: calcium-based (calcium carbonate, calcium acetate), non-calcium (sevelamer, lanthanum), and iron-based (ferric citrate, sucroferric oxyhydroxide). They must be taken with food to bind the phosphate in that meal - timing with the meal is what makes them work. Binder choice weighs phosphate efficacy against calcium load (calcification risk), pill burden, and cost. Dietary phosphate restriction alone rarely achieves targets; binders plus diet plus adequate dialysis are the three pillars of phosphate management in CKD-MBD.
Blood phosphate above ~5.5 mg/dL - a CKD mineral-bone disorder driver that accelerates vascular calcification and bone disease.
Overactive parathyroid glands caused by kidney failure — driven by low vitamin D, high phosphate, and low calcium — damaging bones and vessels if untreated.
A medication that binds potassium in the gut to lower blood potassium — allowing patients with CKD to stay on protective ACEi/ARB therapy.
A progressive condition characterized by gradual loss of kidney function over months or years, classified into 5 stages based on eGFR.
ZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime